Behind every peptide project, there are people making the work possible.From research and production to quality, operations, and customer support, Labor Day is the perfect time to recognize the teams whose dedication makes everything possible, every day.Happy Labor...
JYMed Peptide’s New Semaglutide DMF No. 041090 Listed as “Available for Reference” by the U.S. FDA JYMed Peptide recently announced that an additional Drug Master File (DMF) for its Semaglutide active pharmaceutical ingredient (API), DMF No. 041090, has successfully...
Recently, Hubei JXBio Pharmaceutical Co., Ltd. (“Hubei JXBio”), the peptide manufacturing base of Jianyuan Pharmaceuticals, received the Chemical API Marketing Approval Notification for Icatibant Acetate (Registration No.: Y20240000910) issued by...
To Our Valued Clients, Partners, and Friends, We are pleased to announce the appointment of Dr. ZhaoBo Gao as Chief Operating Officer (COO) of JYMed Peptide. Dr. Gao brings more than 20 years of successful experience in multinational corporations and leading CDMO...
Date: March 2026 | 1. FDA Crackdown on Unapproved Compounded GLP-1 Products The U.S. FDA issued 30 warning letters to telehealth companies and compounding pharmacies marketing unapproved compounded GLP-1 products (e.g., semaglutide, tirzepatide) with false efficacy...
JYMed is pleased to announce that the U.S. Food and Drug Administration has acknowledged receipt of a new Type II Drug Master File for semaglutide API manufactured under a new process. FDA acknowledgment letter for JYMed’s Type II DMF filing for semaglutide API...
中文
